Subscribe

NGL Fine-Chem Limited (NGLFINE.NS)

INR3,165.50 +34.70 (+1.11%)
IN NSE Healthcare Drug Manufacturers - General
Address 301, E Square 400057
Mumbai, IN
CEO Rahul Jayant Nachane
Website nglfinechem.com
IPO 2022-07-08
ISIN INE887E01022

Explore sections of this company profile

Also trades on Bombay Stock Exchange · NGLFINE.BO (INR) National Stock Exchange of India · NGLFINE.NS (INR)
Description

Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR3,165.50 +34.70 (+1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18.9K
Beta
0.63
Float Shares
1.58M
Free Float %
25.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+11.95% +18.22% +25.27% +24.23% +112.02% +99.19% +126.97% +87.14% +49.87% +49.87% +49.87%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
3,165.50
Quality scores
Altman Z-Score
6.28
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - General: +6.6%
    +36.0% ★ Q1'26: +57.1% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - General: +18.2%
    +127.8% ★ Q1'26: +2,380.7% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +0.6% Q1'26: -5.5% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +10.6% Q1'26: +11.0% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +10.3% ★ Q1'26: +12.6% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    0.0% ★ Q1'26: +0.0% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    1.49× Q1'26: 1.27× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.55) × ERP
WACC = 94% × Ke + 6% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 3,165.50
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana. 		Mar 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
883.28M
est: 883.28M (0.0%)
962.93M
est: 971.61M (-0.9%)
1.00B
est: 1.02B (-2.2%)
1.11B
est: 1.13B (-1.5%)
1.51B
est: 1.53B (-1.3%)
1.49B
est: 1.79B (-16.9%)
2.58B
est: 2.06B (+25.2%)
3.68B
est: 883.28M (+316.9%)
971.61M
971.61M – 971.61M
+10.0% YoY
1.02B
1.02B – 1.02B
+5.4% YoY
1.13B
1.13B – 1.13B
+10.0% YoY
1.53B
1.53B – 1.53B
+35.5% YoY
1.79B
1.79B – 1.79B
+17.4% YoY
2.06B
2.06B – 2.06B
+15.0% YoY
EBITDA
170.06M
est: 181.60M (-6.4%)
221.59M
est: 199.76M (+10.9%)
268.97M
est: 210.55M (+27.7%)
241.30M
est: 231.63M (+4.2%)
361.54M
est: 313.94M (+15.2%)
228.10M
est: 368.46M (-38.1%)
881.27M
est: 423.73M (+108.0%)
338.69M
est: 146.89M (+130.6%)
161.58M
161.58M – 161.58M
+10.0% YoY
170.31M
170.31M – 170.31M
+5.4% YoY
187.35M
187.35M – 187.35M
+10.0% YoY
253.93M
253.93M – 253.93M
+35.5% YoY
298.03M
298.03M – 298.03M
+17.4% YoY
342.73M
342.73M – 342.73M
+15.0% YoY
EBIT
141.14M
est: 150.91M (-6.5%)
190.41M
est: 166.00M (+14.7%)
235.34M
est: 174.97M (+34.5%)
193.58M
est: 192.48M (+0.6%)
298.54M
est: 260.88M (+14.4%)
143.27M
est: 306.19M (-53.2%)
794.30M
est: 352.11M (+125.6%)
214.18M
est: 114.99M (+86.3%)
126.49M
126.49M – 126.49M
+10.0% YoY
133.33M
133.33M – 133.33M
+5.4% YoY
146.67M
146.67M – 146.67M
+10.0% YoY
198.79M
198.79M – 198.79M
+35.5% YoY
233.32M
233.32M – 233.32M
+17.4% YoY
268.32M
268.32M – 268.32M
+15.0% YoY
Net Income
83.30M
est: 83.29M (+0.0%)
113.98M
est: 107.14M (+6.4%)
142.39M
est: 149.84M (-5.0%)
125.93M
est: 137.17M (-8.2%)
201.27M
est: 187.53M (+7.3%)
83.35M
est: 240.30M (-65.3%)
567.19M
est: 275.21M (+106.1%)
211.24M
est: 83.28M (+153.7%)
107.13M
107.13M – 107.13M
+28.6% YoY
149.82M
149.82M – 149.82M
+39.9% YoY
137.15M
137.15M – 137.15M
-8.5% YoY
187.50M
187.50M – 187.50M
+36.7% YoY
240.26M
240.26M – 240.26M
+28.1% YoY
275.17M
275.17M – 275.17M
+14.5% YoY
SGA
65.51M
est: 72.44M (-9.6%)
94.74M
est: 79.68M (+18.9%)
45.69M
est: 83.99M (-45.6%)
59.82M
est: 92.40M (-35.3%)
69.61M
est: 125.23M (-44.4%)
78.60M
est: 146.98M (-46.5%)
126.42M
est: 169.02M (-25.2%)
576.65M
est: 107.25M (+437.6%)
117.98M
117.98M – 117.98M
+10.0% YoY
124.35M
124.35M – 124.35M
+5.4% YoY
136.80M
136.80M – 136.80M
+10.0% YoY
185.41M
185.41M – 185.41M
+35.5% YoY
217.61M
217.61M – 217.61M
+17.4% YoY
250.26M
250.26M – 250.26M
+15.0% YoY
EPS
13.48
est: 13.48 (+0.0%)
18.45
est: 17.34 (+6.4%)
24.09
est: 24.25 (-0.7%)
20.38
est: 22.20 (-8.2%)
32.58
est: 30.35 (+7.3%)
13.49
est: 38.89 (-65.3%)
91.81
est: 44.54 (+106.1%)
34.19
est: 13.48 (+153.6%)
17.34
17.34 – 17.34
+28.6% YoY
24.25
24.25 – 24.25
+39.9% YoY
22.20
22.20 – 22.20
-8.5% YoY
30.35
30.35 – 30.35
+36.7% YoY
38.89
38.89 – 38.89
+28.1% YoY
44.54
44.54 – 44.54
+14.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 3/5 1/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 3/5 1/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 3/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 2/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
72.89M
OE per share TTM
11.80
Owner's Yield
0.43%
Maintenance CapEx ratio
142.47%
Maint CapEx / Avg PPE
42.2%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
778.7K
Shares Outstanding
6.18M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Rahul Jayant Nachane Chief Executive Officer, MD, Chief Ethics Counsellor & Executive Director 18M male
Rajesh Narayan Lawande Whole Time Director & Chief Financial Officer 18M male
Ahaan Nachane Vice President — male
Shivam Gharat Company Secretary & Compliance Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General